If hypersensitivity reaction or chemical irritation occurs with the use of Mupi, treatment should be discontinued and appropriate alternative therapy for the infection instituted.
As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi.
Mupi is not formulated for use on mucosal surfaces. Intranasal use has been associated with isolated reports of stinging pain and drying.
Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by the kidneys. In common with other polyethylene glycol-based ointment, Mupi should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment.
Use in pregnancy & lactation: Reproduction studies have been performed in rats and rabbits at systemic doses ie, orally, SC and IM, up to 100 times the human topical dose and have revealed no evidence of impaired fertility or harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, mupirocin should be used during pregnancy only if clearly needed.
It is not known whether mupirocin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when mupirocin is given to nursing mothers.
Use in children: The safety and effectiveness of mupirocin have been established in the age range of 2 months to 16 years. Use of mupirocin in these age groups is supported by evidence from adequate and well-controlled studies.